Off label treatments – analysis, characteristic and therapeutic aims Review article
Article Sidebar
Published:
Sep 30, 2013
Keywords:
product characteristics, off label, empirical, tolperisone
Main Article Content
Abstract
The use of drugs beyond the indications given in the Product Characteristics is a common clinical practice, seen in many areas of medicine. It enables expanding the use of the drug for those that have not been tested meets the criteria for registration. In many cases it is the only way to treat the disease or reduce the severity of its symptoms.
Article Details
How to Cite
Bednarczyk, D., & Zaborski, J. (2013). Off label treatments – analysis, characteristic and therapeutic aims. Medycyna Faktow (J EBM), 6(3(20), 9-13. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2401
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Radley D., Finkelstein S., Stafford R.: Off-label Prescribing Among Office-Based Physicians. Archives of Internal Medicine 2006; 9: 1021-1026.
2. Serafin A.: Stosowanie leków poza wskazaniami. Aptekarz Polski 2011; 60: 24.
3. Kocsis P., Farkas S., Fodor L. et al.: Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. J. Pharmacol. Exp. Ther. 2005; 315(3): 1237-46.
4. Pratzel H.G., Alken R.G., Ramm S.: Efficacy and tolerance of repeated oral doses of tolperisone hydrochloride in the treatment of painful reflex muscle spasm: results of a prospective placebo-controlled double-blind trial. Pain 1996; 67(2-3): 417-25.
5. Rao R. , Panghate A. , Chandanwale A. et al.: Clinical Comparative Study: Efficacy and Tolerability of Tolperisone and Thiocolchicoside in Acute Low Back Pain and Spinal Muscle Spasticity. Asian Spine J. 2012; 6(2): 115-122.
6. Dulin J., Kovács L., Ramm S. et al.: Evaluation of sedative effects of single and repeated doses of 50 mg and 150 mg tolperisone hydrochloride. Results of a prospective, randomized, double-blind, placebo-controlled trial. Pharmacopsychiatry 1998; 31(4): 137-42.
7. Camargos E.F., Oliveira L.F., Boaventura T.D. et al.: Mianserin for the treatment of sleep disorders in patients with dementia: a retrospective open-label study. J. Clin. Psychopharmacol. 2012; 32(4): 576-8.
8. Birks J., McGuinness B., Craig D.: Rivastigmine for vascular cognitive impairment. Cochrane Database Syst. Rev. 2013 May 31; 5: CD004744.
9. Vidal J.S., Lacombe J.M., Dartigues J.F. et al.: Evaluation of the impact of memantine treatment initiation on psychotropics use: a study from the French national health care database. Neuroepidemiology 2008; 31(3): 193-200.
10. Modlińska A., Wolnik B.: Chory z zaburzeniami kontroli glikemii w opiece paliatywnej. Medycyna Paliatywna 2013; 5(1): 1-7.
2. Serafin A.: Stosowanie leków poza wskazaniami. Aptekarz Polski 2011; 60: 24.
3. Kocsis P., Farkas S., Fodor L. et al.: Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. J. Pharmacol. Exp. Ther. 2005; 315(3): 1237-46.
4. Pratzel H.G., Alken R.G., Ramm S.: Efficacy and tolerance of repeated oral doses of tolperisone hydrochloride in the treatment of painful reflex muscle spasm: results of a prospective placebo-controlled double-blind trial. Pain 1996; 67(2-3): 417-25.
5. Rao R. , Panghate A. , Chandanwale A. et al.: Clinical Comparative Study: Efficacy and Tolerability of Tolperisone and Thiocolchicoside in Acute Low Back Pain and Spinal Muscle Spasticity. Asian Spine J. 2012; 6(2): 115-122.
6. Dulin J., Kovács L., Ramm S. et al.: Evaluation of sedative effects of single and repeated doses of 50 mg and 150 mg tolperisone hydrochloride. Results of a prospective, randomized, double-blind, placebo-controlled trial. Pharmacopsychiatry 1998; 31(4): 137-42.
7. Camargos E.F., Oliveira L.F., Boaventura T.D. et al.: Mianserin for the treatment of sleep disorders in patients with dementia: a retrospective open-label study. J. Clin. Psychopharmacol. 2012; 32(4): 576-8.
8. Birks J., McGuinness B., Craig D.: Rivastigmine for vascular cognitive impairment. Cochrane Database Syst. Rev. 2013 May 31; 5: CD004744.
9. Vidal J.S., Lacombe J.M., Dartigues J.F. et al.: Evaluation of the impact of memantine treatment initiation on psychotropics use: a study from the French national health care database. Neuroepidemiology 2008; 31(3): 193-200.
10. Modlińska A., Wolnik B.: Chory z zaburzeniami kontroli glikemii w opiece paliatywnej. Medycyna Paliatywna 2013; 5(1): 1-7.